The effect of Org GC 94 on thrombocyte function, blood coagulation and the fibrinolytic system in man.
The effect of a 14 day treatment with Org GC 94 in rising dosage to a maximum of 45 mg/day on thrombocyte function, blood coagulation and the fibrinolytic system was investigated in 16 healthy volunteers in a double-blind comparative trial with placebo. At the same time the influence on some liver function tests and on the general condition of the subjects was followed. Analysis of the data obtained in tests pertaining to platelet function, blood coagulation, fibrinolysis and liver function did not indicate unwanted or harmful effects of Org GC 94. No significant difference in effect between Org GC 94 and placebo was detectable. The general physical condition including appetite and body weight was not affected by Org GC 94. A mild, transient sedative effect of the maximum dose of Org GC 94 is likely and some influence upon concentration (decrease) and mood (indifference or elevation) in some subjects cannot be excluded.
D000293:Adolescent; D000328:Adult; D001066:Appetite / Q000187:drug effects; D001288:Attention / Q000187:drug effects; D001777:Blood Coagulation / Q000187:drug effects*; D001792:Blood Platelets / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects; D003989:Dibenzoxazepines / Q000494:pharmacology*; D004644:Emotions / Q000187:drug effects; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D006993:Hypnotics and Sedatives; D008111:Liver Function Tests
D003989:Dibenzoxazepines; D006993:Hypnotics and Sedatives